P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis Article Swipe
Laurent Peyrin‐Biroulet
,
Peter Bossuyt
,
Dominik Bettenworth
,
Edward V. Loftus
,
S Anjie
,
Geert D’Haens
,
Masayuki Saruta
,
Perttu Arkkila
,
D H Kim
,
Dasom Choi
,
Walter Reinisch
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0575
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0575
Background Network meta-analysis (NMA) using randomised controlled trial (RCT) data can provide indirect evidence on comparative efficacy of various treatments.1 The NMA reported herein was conducted to evaluate infliximab (IFX) and vedolizumab (VDZ) comparative efficacy during maintenance treatment of moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC), covering various dosing regimens and administration routes for each biologic. Methods Studies were identified by literature searches that included publications up to 1 November 2022. Parallel-group RCTs evaluating IFX or VDZ (intravenous [IV] or subcutaneous [SC]) for maintenance treatment of adult patients with moderate-to-severe CD or UC that reported clinical remission rates were included. Eligible studies treated patients for a minimum of 22 weeks, with follow-up of 30–60 weeks for maintenance. Clinical remission rates in tumour necrosis factor inhibitor (TNFi)-naïve patients from each study were analysed in a Bayesian NMA fixed-effect model. Results Overall, 13 RCTs were identified and included in the analysis (Table 1 for CD and Table 2 for UC). The difference in study design between IFX (treat-through) and VDZ (re-randomisation of induction responders only) was noted. A connected network of evidence could be generated using CD and UC studies (Figures 1A and 1B, respectively). In both CD and UC, IFX SC 120 mg had the highest odds ratio (95% confidence interval [CI]) vs. placebo for clinical remission during the maintenance phase (CD: 5.90 [1.90–18.2]; UC: 5.45 [1.94–15.3]), albeit with the CIs overlapping with the CIs of the other tested regimens (Figures 2A and 2B). In both CD and UC, IFX SC 120 mg ranked highest for clinical remission among the biological agents, dosing regimens, and routes of administration tested. Conclusion In both CD and UC, IFX SC showed a favourable efficacy profile for achieving clinical remission during maintenance treatment of TNFi-naïve adult patients, when compared with the other IFX IV or VDZ IV/SC regimens tested. References: 1 Rouse B et al., Intern Emerg Med 2017;12(1):103-111.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ecco-jcc/jjac190.0575
- https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdf
- OA Status
- bronze
- Cited By
- 1
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4318539898
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4318539898Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ecco-jcc/jjac190.0575Digital Object Identifier
- Title
-
P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative ColitisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-01-30Full publication date if available
- Authors
-
Laurent Peyrin‐Biroulet, Peter Bossuyt, Dominik Bettenworth, Edward V. Loftus, S Anjie, Geert D’Haens, Masayuki Saruta, Perttu Arkkila, D H Kim, Dasom Choi, Walter ReinischList of authors in order
- Landing page
-
https://doi.org/10.1093/ecco-jcc/jjac190.0575Publisher landing page
- PDF URL
-
https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdfDirect OA link when available
- Concepts
-
Vedolizumab, Medicine, Internal medicine, Infliximab, Ulcerative colitis, Odds ratio, Maintenance therapy, Placebo, Gastroenterology, Randomized controlled trial, Dosing, Confidence interval, Crohn's disease, Surgery, Disease, Chemotherapy, Pathology, Alternative medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4318539898 |
|---|---|
| doi | https://doi.org/10.1093/ecco-jcc/jjac190.0575 |
| ids.doi | https://doi.org/10.1093/ecco-jcc/jjac190.0575 |
| ids.openalex | https://openalex.org/W4318539898 |
| fwci | 0.35927246 |
| type | article |
| title | P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis |
| biblio.issue | Supplement_1 |
| biblio.volume | 17 |
| biblio.last_page | i576 |
| biblio.first_page | i574 |
| topics[0].id | https://openalex.org/T10134 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9994999766349792 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1311 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Inflammatory Bowel Disease |
| topics[1].id | https://openalex.org/T11616 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9573000073432922 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2720 |
| topics[1].subfield.display_name | Hematology |
| topics[1].display_name | Autoimmune and Inflammatory Disorders Research |
| topics[2].id | https://openalex.org/T12255 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9352999925613403 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Biosimilars and Bioanalytical Methods |
| is_xpac | False |
| apc_list.value | 3881 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4185 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776207728 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9443279504776001 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7918002 |
| concepts[0].display_name | Vedolizumab |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8889676332473755 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7790495157241821 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C2777138892 |
| concepts[3].level | 3 |
| concepts[3].score | 0.7614957094192505 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q415264 |
| concepts[3].display_name | Infliximab |
| concepts[4].id | https://openalex.org/C2780479503 |
| concepts[4].level | 3 |
| concepts[4].score | 0.7375478744506836 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1477 |
| concepts[4].display_name | Ulcerative colitis |
| concepts[5].id | https://openalex.org/C156957248 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6024620532989502 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1862216 |
| concepts[5].display_name | Odds ratio |
| concepts[6].id | https://openalex.org/C2778283404 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5657460689544678 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q6736822 |
| concepts[6].display_name | Maintenance therapy |
| concepts[7].id | https://openalex.org/C27081682 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5377832055091858 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[7].display_name | Placebo |
| concepts[8].id | https://openalex.org/C90924648 |
| concepts[8].level | 1 |
| concepts[8].score | 0.5078278183937073 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[8].display_name | Gastroenterology |
| concepts[9].id | https://openalex.org/C168563851 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4652669429779053 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[9].display_name | Randomized controlled trial |
| concepts[10].id | https://openalex.org/C2777288759 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4471302330493927 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q4164182 |
| concepts[10].display_name | Dosing |
| concepts[11].id | https://openalex.org/C44249647 |
| concepts[11].level | 2 |
| concepts[11].score | 0.4396355152130127 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[11].display_name | Confidence interval |
| concepts[12].id | https://openalex.org/C2779280984 |
| concepts[12].level | 3 |
| concepts[12].score | 0.4371013641357422 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1472 |
| concepts[12].display_name | Crohn's disease |
| concepts[13].id | https://openalex.org/C141071460 |
| concepts[13].level | 1 |
| concepts[13].score | 0.37414488196372986 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[13].display_name | Surgery |
| concepts[14].id | https://openalex.org/C2779134260 |
| concepts[14].level | 2 |
| concepts[14].score | 0.24322232604026794 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[14].display_name | Disease |
| concepts[15].id | https://openalex.org/C2776694085 |
| concepts[15].level | 2 |
| concepts[15].score | 0.09232363104820251 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[15].display_name | Chemotherapy |
| concepts[16].id | https://openalex.org/C142724271 |
| concepts[16].level | 1 |
| concepts[16].score | 0.06024762988090515 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[16].display_name | Pathology |
| concepts[17].id | https://openalex.org/C204787440 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[17].display_name | Alternative medicine |
| keywords[0].id | https://openalex.org/keywords/vedolizumab |
| keywords[0].score | 0.9443279504776001 |
| keywords[0].display_name | Vedolizumab |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8889676332473755 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.7790495157241821 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/infliximab |
| keywords[3].score | 0.7614957094192505 |
| keywords[3].display_name | Infliximab |
| keywords[4].id | https://openalex.org/keywords/ulcerative-colitis |
| keywords[4].score | 0.7375478744506836 |
| keywords[4].display_name | Ulcerative colitis |
| keywords[5].id | https://openalex.org/keywords/odds-ratio |
| keywords[5].score | 0.6024620532989502 |
| keywords[5].display_name | Odds ratio |
| keywords[6].id | https://openalex.org/keywords/maintenance-therapy |
| keywords[6].score | 0.5657460689544678 |
| keywords[6].display_name | Maintenance therapy |
| keywords[7].id | https://openalex.org/keywords/placebo |
| keywords[7].score | 0.5377832055091858 |
| keywords[7].display_name | Placebo |
| keywords[8].id | https://openalex.org/keywords/gastroenterology |
| keywords[8].score | 0.5078278183937073 |
| keywords[8].display_name | Gastroenterology |
| keywords[9].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[9].score | 0.4652669429779053 |
| keywords[9].display_name | Randomized controlled trial |
| keywords[10].id | https://openalex.org/keywords/dosing |
| keywords[10].score | 0.4471302330493927 |
| keywords[10].display_name | Dosing |
| keywords[11].id | https://openalex.org/keywords/confidence-interval |
| keywords[11].score | 0.4396355152130127 |
| keywords[11].display_name | Confidence interval |
| keywords[12].id | https://openalex.org/keywords/crohns-disease |
| keywords[12].score | 0.4371013641357422 |
| keywords[12].display_name | Crohn's disease |
| keywords[13].id | https://openalex.org/keywords/surgery |
| keywords[13].score | 0.37414488196372986 |
| keywords[13].display_name | Surgery |
| keywords[14].id | https://openalex.org/keywords/disease |
| keywords[14].score | 0.24322232604026794 |
| keywords[14].display_name | Disease |
| keywords[15].id | https://openalex.org/keywords/chemotherapy |
| keywords[15].score | 0.09232363104820251 |
| keywords[15].display_name | Chemotherapy |
| keywords[16].id | https://openalex.org/keywords/pathology |
| keywords[16].score | 0.06024762988090515 |
| keywords[16].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.1093/ecco-jcc/jjac190.0575 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735960814 |
| locations[0].source.issn | 1873-9946, 1876-4479 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1873-9946 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Crohn s and Colitis |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Crohn's and Colitis |
| locations[0].landing_page_url | https://doi.org/10.1093/ecco-jcc/jjac190.0575 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5042884495 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-2536-6618 |
| authorships[0].author.display_name | Laurent Peyrin‐Biroulet |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210100260 |
| authorships[0].affiliations[0].raw_affiliation_string | Centre Hospitalier Régional Universitaire de Nancy, Department of Gastroenterology , Nancy, France |
| authorships[0].institutions[0].id | https://openalex.org/I4210100260 |
| authorships[0].institutions[0].ror | https://ror.org/016ncsr12 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210100260 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Centre Hospitalier Régional et Universitaire de Nancy |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | L Peyrin-Biroulet |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Centre Hospitalier Régional Universitaire de Nancy, Department of Gastroenterology , Nancy, France |
| authorships[1].author.id | https://openalex.org/A5021791508 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4027-7365 |
| authorships[1].author.display_name | Peter Bossuyt |
| authorships[1].countries | BE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210135614 |
| authorships[1].affiliations[0].raw_affiliation_string | Imelda GI Clinical Research Centre, Imelda General Hospital , Bonheiden, Belgium |
| authorships[1].institutions[0].id | https://openalex.org/I4210135614 |
| authorships[1].institutions[0].ror | https://ror.org/037s71n47 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210135614 |
| authorships[1].institutions[0].country_code | BE |
| authorships[1].institutions[0].display_name | Imelda Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | P Bossuyt |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Imelda GI Clinical Research Centre, Imelda General Hospital , Bonheiden, Belgium |
| authorships[2].author.id | https://openalex.org/A5075650830 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-1435-4825 |
| authorships[2].author.display_name | Dominik Bettenworth |
| authorships[2].countries | DE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I22465464 |
| authorships[2].affiliations[0].raw_affiliation_string | University of Münster, Medical Faculty , Münster, Germany |
| authorships[2].institutions[0].id | https://openalex.org/I22465464 |
| authorships[2].institutions[0].ror | https://ror.org/00pd74e08 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I22465464 |
| authorships[2].institutions[0].country_code | DE |
| authorships[2].institutions[0].display_name | University of Münster |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | D Bettenworth |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | University of Münster, Medical Faculty , Münster, Germany |
| authorships[3].author.id | https://openalex.org/A5056735741 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7199-6851 |
| authorships[3].author.display_name | Edward V. Loftus |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1330342723 |
| authorships[3].affiliations[0].raw_affiliation_string | Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology , Rochester, United States |
| authorships[3].institutions[0].id | https://openalex.org/I1330342723 |
| authorships[3].institutions[0].ror | https://ror.org/02qp3tb03 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1330342723 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Mayo Clinic |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | E V Loftus Jr. |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology , Rochester, United States |
| authorships[4].author.id | https://openalex.org/A5001506471 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | S Anjie |
| authorships[4].countries | NL |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210151833, https://openalex.org/I887064364 |
| authorships[4].affiliations[0].raw_affiliation_string | Amsterdam UMC University of Amsterdam, Department of Gastroenterology and Hepatology , Amsterdam, The Netherlands |
| authorships[4].institutions[0].id | https://openalex.org/I4210151833 |
| authorships[4].institutions[0].ror | https://ror.org/05grdyy37 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210151833 |
| authorships[4].institutions[0].country_code | NL |
| authorships[4].institutions[0].display_name | Amsterdam University Medical Centers |
| authorships[4].institutions[1].id | https://openalex.org/I887064364 |
| authorships[4].institutions[1].ror | https://ror.org/04dkp9463 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I887064364 |
| authorships[4].institutions[1].country_code | NL |
| authorships[4].institutions[1].display_name | University of Amsterdam |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | S Anjie |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Amsterdam UMC University of Amsterdam, Department of Gastroenterology and Hepatology , Amsterdam, The Netherlands |
| authorships[5].author.id | https://openalex.org/A5057899912 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-2784-4046 |
| authorships[5].author.display_name | Geert D’Haens |
| authorships[5].countries | NL |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210151833, https://openalex.org/I887064364 |
| authorships[5].affiliations[0].raw_affiliation_string | Amsterdam UMC University of Amsterdam, Department of Gastroenterology and Hepatology , Amsterdam, The Netherlands |
| authorships[5].institutions[0].id | https://openalex.org/I4210151833 |
| authorships[5].institutions[0].ror | https://ror.org/05grdyy37 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210151833 |
| authorships[5].institutions[0].country_code | NL |
| authorships[5].institutions[0].display_name | Amsterdam University Medical Centers |
| authorships[5].institutions[1].id | https://openalex.org/I887064364 |
| authorships[5].institutions[1].ror | https://ror.org/04dkp9463 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I887064364 |
| authorships[5].institutions[1].country_code | NL |
| authorships[5].institutions[1].display_name | University of Amsterdam |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | G D’Haens |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Amsterdam UMC University of Amsterdam, Department of Gastroenterology and Hepatology , Amsterdam, The Netherlands |
| authorships[6].author.id | https://openalex.org/A5054899877 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-8172-3240 |
| authorships[6].author.display_name | Masayuki Saruta |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I115498069 |
| authorships[6].affiliations[0].raw_affiliation_string | The Jikei University School of Medicine, Department of Internal Medicine , Tokyo, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I115498069 |
| authorships[6].institutions[0].ror | https://ror.org/039ygjf22 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I115498069 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Jikei University School of Medicine |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | M Saruta |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | The Jikei University School of Medicine, Department of Internal Medicine , Tokyo, Japan |
| authorships[7].author.id | https://openalex.org/A5005213853 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-2194-0424 |
| authorships[7].author.display_name | Perttu Arkkila |
| authorships[7].countries | FI |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I2800394112 |
| authorships[7].affiliations[0].raw_affiliation_string | Helsinki University Hospital, Department of Gastroenterology , Helsinki, Finland |
| authorships[7].institutions[0].id | https://openalex.org/I2800394112 |
| authorships[7].institutions[0].ror | https://ror.org/02e8hzf44 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2800394112, https://openalex.org/I4210166427 |
| authorships[7].institutions[0].country_code | FI |
| authorships[7].institutions[0].display_name | Helsinki University Hospital |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | P Arkkila |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Helsinki University Hospital, Department of Gastroenterology , Helsinki, Finland |
| authorships[8].author.id | https://openalex.org/A5033611801 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | D H Kim |
| authorships[8].countries | KR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210158021 |
| authorships[8].affiliations[0].raw_affiliation_string | Celltrion Healthcare Co., Ltd , Incheon, Korea- Republic Of |
| authorships[8].institutions[0].id | https://openalex.org/I4210158021 |
| authorships[8].institutions[0].ror | https://ror.org/05k84m754 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210158021 |
| authorships[8].institutions[0].country_code | KR |
| authorships[8].institutions[0].display_name | Celltrion (South Korea) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | D H Kim |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Celltrion Healthcare Co., Ltd , Incheon, Korea- Republic Of |
| authorships[9].author.id | https://openalex.org/A5101730957 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-6280-3840 |
| authorships[9].author.display_name | Dasom Choi |
| authorships[9].countries | KR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210158021 |
| authorships[9].affiliations[0].raw_affiliation_string | Celltrion Healthcare Co., Ltd , Incheon, Korea- Republic Of |
| authorships[9].institutions[0].id | https://openalex.org/I4210158021 |
| authorships[9].institutions[0].ror | https://ror.org/05k84m754 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210158021 |
| authorships[9].institutions[0].country_code | KR |
| authorships[9].institutions[0].display_name | Celltrion (South Korea) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | D Choi |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Celltrion Healthcare Co., Ltd , Incheon, Korea- Republic Of |
| authorships[10].author.id | https://openalex.org/A5111824557 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Walter Reinisch |
| authorships[10].countries | AT |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I76134821 |
| authorships[10].affiliations[0].raw_affiliation_string | Medical University of Vienna, Department of Internal Medicine III , Vienna, Austria |
| authorships[10].institutions[0].id | https://openalex.org/I76134821 |
| authorships[10].institutions[0].ror | https://ror.org/05n3x4p02 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I76134821 |
| authorships[10].institutions[0].country_code | AT |
| authorships[10].institutions[0].display_name | Medical University of Vienna |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | W Reinisch |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Medical University of Vienna, Department of Internal Medicine III , Vienna, Austria |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10134 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9994999766349792 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1311 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Inflammatory Bowel Disease |
| related_works | https://openalex.org/W2800161339, https://openalex.org/W2411642353, https://openalex.org/W2314938982, https://openalex.org/W4380488883, https://openalex.org/W2092387047, https://openalex.org/W2318573456, https://openalex.org/W2789988551, https://openalex.org/W4309412776, https://openalex.org/W2319769311, https://openalex.org/W4229523599 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/ecco-jcc/jjac190.0575 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735960814 |
| best_oa_location.source.issn | 1873-9946, 1876-4479 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1873-9946 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Crohn s and Colitis |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Crohn's and Colitis |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ecco-jcc/jjac190.0575 |
| primary_location.id | doi:10.1093/ecco-jcc/jjac190.0575 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735960814 |
| primary_location.source.issn | 1873-9946, 1876-4479 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1873-9946 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Crohn s and Colitis |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i574/49367973/jjac190.0575.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Crohn's and Colitis |
| primary_location.landing_page_url | https://doi.org/10.1093/ecco-jcc/jjac190.0575 |
| publication_date | 2023-01-30 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 70, 152, 307 |
| abstract_inverted_index.2 | 157 |
| abstract_inverted_index.A | 177 |
| abstract_inverted_index.B | 309 |
| abstract_inverted_index.a | 107, 135, 279 |
| abstract_inverted_index.13 | 142 |
| abstract_inverted_index.1A | 191 |
| abstract_inverted_index.22 | 110 |
| abstract_inverted_index.2A | 242 |
| abstract_inverted_index.CD | 92, 154, 186, 197, 247, 273 |
| abstract_inverted_index.IV | 300 |
| abstract_inverted_index.In | 195, 245, 271 |
| abstract_inverted_index.SC | 201, 251, 277 |
| abstract_inverted_index.UC | 94, 188 |
| abstract_inverted_index.be | 183 |
| abstract_inverted_index.by | 62 |
| abstract_inverted_index.et | 310 |
| abstract_inverted_index.in | 122, 134, 148, 162 |
| abstract_inverted_index.mg | 203, 253 |
| abstract_inverted_index.of | 18, 39, 87, 109, 114, 171, 180, 236, 267, 290 |
| abstract_inverted_index.on | 15 |
| abstract_inverted_index.or | 77, 81, 93, 301 |
| abstract_inverted_index.to | 27, 69 |
| abstract_inverted_index.up | 68 |
| abstract_inverted_index.120 | 202, 252 |
| abstract_inverted_index.1B, | 193 |
| abstract_inverted_index.CIs | 231, 235 |
| abstract_inverted_index.IFX | 76, 166, 200, 250, 276, 299 |
| abstract_inverted_index.Med | 314 |
| abstract_inverted_index.NMA | 22, 137 |
| abstract_inverted_index.The | 21, 160 |
| abstract_inverted_index.UC, | 199, 249, 275 |
| abstract_inverted_index.UC: | 225 |
| abstract_inverted_index.VDZ | 78, 169, 302 |
| abstract_inverted_index.and | 31, 44, 52, 146, 155, 168, 187, 192, 198, 243, 248, 265, 274 |
| abstract_inverted_index.can | 11 |
| abstract_inverted_index.for | 55, 84, 106, 117, 153, 158, 215, 256, 283 |
| abstract_inverted_index.had | 204 |
| abstract_inverted_index.the | 149, 205, 219, 230, 234, 237, 260, 297 |
| abstract_inverted_index.vs. | 213 |
| abstract_inverted_index.was | 25, 175 |
| abstract_inverted_index.(95% | 209 |
| abstract_inverted_index.(CD) | 43 |
| abstract_inverted_index.(CD: | 222 |
| abstract_inverted_index.2B). | 244 |
| abstract_inverted_index.5.45 | 226 |
| abstract_inverted_index.5.90 | 223 |
| abstract_inverted_index.RCTs | 74, 143 |
| abstract_inverted_index.UC). | 159 |
| abstract_inverted_index.[IV] | 80 |
| abstract_inverted_index.al., | 311 |
| abstract_inverted_index.both | 196, 246, 272 |
| abstract_inverted_index.data | 10 |
| abstract_inverted_index.each | 56, 130 |
| abstract_inverted_index.from | 129 |
| abstract_inverted_index.odds | 207 |
| abstract_inverted_index.that | 65, 95 |
| abstract_inverted_index.were | 60, 100, 132, 144 |
| abstract_inverted_index.when | 294 |
| abstract_inverted_index.with | 90, 112, 229, 233, 296 |
| abstract_inverted_index.(IFX) | 30 |
| abstract_inverted_index.(NMA) | 4 |
| abstract_inverted_index.(RCT) | 9 |
| abstract_inverted_index.(UC), | 47 |
| abstract_inverted_index.(VDZ) | 33 |
| abstract_inverted_index.2022. | 72 |
| abstract_inverted_index.Emerg | 313 |
| abstract_inverted_index.IV/SC | 303 |
| abstract_inverted_index.Rouse | 308 |
| abstract_inverted_index.Table | 156 |
| abstract_inverted_index.[CI]) | 212 |
| abstract_inverted_index.[SC]) | 83 |
| abstract_inverted_index.adult | 88, 292 |
| abstract_inverted_index.among | 259 |
| abstract_inverted_index.could | 182 |
| abstract_inverted_index.only) | 174 |
| abstract_inverted_index.other | 238, 298 |
| abstract_inverted_index.phase | 221 |
| abstract_inverted_index.rates | 99, 121 |
| abstract_inverted_index.ratio | 208 |
| abstract_inverted_index.study | 131, 163 |
| abstract_inverted_index.trial | 8 |
| abstract_inverted_index.using | 5, 185 |
| abstract_inverted_index.weeks | 116 |
| abstract_inverted_index.(Table | 151 |
| abstract_inverted_index.Intern | 312 |
| abstract_inverted_index.albeit | 228 |
| abstract_inverted_index.design | 164 |
| abstract_inverted_index.dosing | 50, 263 |
| abstract_inverted_index.during | 36, 218, 287 |
| abstract_inverted_index.factor | 125 |
| abstract_inverted_index.herein | 24 |
| abstract_inverted_index.model. | 139 |
| abstract_inverted_index.noted. | 176 |
| abstract_inverted_index.ranked | 254 |
| abstract_inverted_index.routes | 54, 266 |
| abstract_inverted_index.showed | 278 |
| abstract_inverted_index.tested | 239 |
| abstract_inverted_index.tumour | 123 |
| abstract_inverted_index.weeks, | 111 |
| abstract_inverted_index.30–60 | 115 |
| abstract_inverted_index.Methods | 58 |
| abstract_inverted_index.Network | 2 |
| abstract_inverted_index.Results | 140 |
| abstract_inverted_index.Studies | 59 |
| abstract_inverted_index.agents, | 262 |
| abstract_inverted_index.between | 165 |
| abstract_inverted_index.colitis | 46 |
| abstract_inverted_index.disease | 42 |
| abstract_inverted_index.highest | 206, 255 |
| abstract_inverted_index.minimum | 108 |
| abstract_inverted_index.network | 179 |
| abstract_inverted_index.placebo | 214 |
| abstract_inverted_index.profile | 282 |
| abstract_inverted_index.provide | 12 |
| abstract_inverted_index.studies | 103, 189 |
| abstract_inverted_index.tested. | 269, 305 |
| abstract_inverted_index.treated | 104 |
| abstract_inverted_index.various | 19, 49 |
| abstract_inverted_index.(Figures | 190, 241 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Bayesian | 136 |
| abstract_inverted_index.Clinical | 119 |
| abstract_inverted_index.Eligible | 102 |
| abstract_inverted_index.November | 71 |
| abstract_inverted_index.Overall, | 141 |
| abstract_inverted_index.analysed | 133 |
| abstract_inverted_index.analysis | 150 |
| abstract_inverted_index.clinical | 97, 216, 257, 285 |
| abstract_inverted_index.compared | 295 |
| abstract_inverted_index.covering | 48 |
| abstract_inverted_index.efficacy | 17, 35, 281 |
| abstract_inverted_index.evaluate | 28 |
| abstract_inverted_index.evidence | 14, 181 |
| abstract_inverted_index.included | 66, 147 |
| abstract_inverted_index.indirect | 13 |
| abstract_inverted_index.interval | 211 |
| abstract_inverted_index.necrosis | 124 |
| abstract_inverted_index.patients | 89, 105, 128 |
| abstract_inverted_index.regimens | 51, 240, 304 |
| abstract_inverted_index.reported | 23, 96 |
| abstract_inverted_index.searches | 64 |
| abstract_inverted_index.Crohn’s | 41 |
| abstract_inverted_index.achieving | 284 |
| abstract_inverted_index.biologic. | 57 |
| abstract_inverted_index.conducted | 26 |
| abstract_inverted_index.connected | 178 |
| abstract_inverted_index.follow-up | 113 |
| abstract_inverted_index.generated | 184 |
| abstract_inverted_index.included. | 101 |
| abstract_inverted_index.induction | 172 |
| abstract_inverted_index.inhibitor | 126 |
| abstract_inverted_index.patients, | 293 |
| abstract_inverted_index.regimens, | 264 |
| abstract_inverted_index.remission | 98, 120, 217, 258, 286 |
| abstract_inverted_index.treatment | 38, 86, 289 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 270 |
| abstract_inverted_index.biological | 261 |
| abstract_inverted_index.confidence | 210 |
| abstract_inverted_index.controlled | 7 |
| abstract_inverted_index.difference | 161 |
| abstract_inverted_index.evaluating | 75 |
| abstract_inverted_index.favourable | 280 |
| abstract_inverted_index.identified | 61, 145 |
| abstract_inverted_index.infliximab | 29 |
| abstract_inverted_index.literature | 63 |
| abstract_inverted_index.randomised | 6 |
| abstract_inverted_index.responders | 173 |
| abstract_inverted_index.ulcerative | 45 |
| abstract_inverted_index.References: | 306 |
| abstract_inverted_index.TNFi-naïve | 291 |
| abstract_inverted_index.comparative | 16, 34 |
| abstract_inverted_index.maintenance | 37, 85, 220, 288 |
| abstract_inverted_index.overlapping | 232 |
| abstract_inverted_index.vedolizumab | 32 |
| abstract_inverted_index.(intravenous | 79 |
| abstract_inverted_index.fixed-effect | 138 |
| abstract_inverted_index.maintenance. | 118 |
| abstract_inverted_index.publications | 67 |
| abstract_inverted_index.subcutaneous | 82 |
| abstract_inverted_index.treatments.1 | 20 |
| abstract_inverted_index.(TNFi)-naïve | 127 |
| abstract_inverted_index.meta-analysis | 3 |
| abstract_inverted_index.Parallel-group | 73 |
| abstract_inverted_index.[1.90–18.2]; | 224 |
| abstract_inverted_index.administration | 53, 268 |
| abstract_inverted_index.respectively). | 194 |
| abstract_inverted_index.(treat-through) | 167 |
| abstract_inverted_index.[1.94–15.3]), | 227 |
| abstract_inverted_index.(re-randomisation | 170 |
| abstract_inverted_index.moderate-to-severe | 40, 91 |
| abstract_inverted_index.2017;12(1):103-111. | 315 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 9 |
| institutions_distinct_count | 11 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7799999713897705 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.66339695 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |